UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Results from a phase 3 clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent ...

In a country where the shortage of donor corneas often stands between a patient and restored vision, an innovative eye ...

Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms, according to a study published ...

A 22-year-old Bolton man’s death was the result of a “gross failure to provide basic medical care” an inquest has concluded.

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

Experiencing a migraine involves severe headaches, but they don’t show up alone. They are often accompanied by what the Mayo ...

Ubrogepant, approved for acute treatment of migraine, may also reduce nonheadache symptoms that occur in the hours preceding ...

Patna: With temperatures soaring in the city, heat-related health complaints have surged, including cases of diarrhoea, ...

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent ...